Rituximab-induced lung disease.

Area of Science:

• Oncology
• Pulmonology
• Immunology

Background:

• Rituximab is a widely used monoclonal antibody therapy.
• While generally safe, Rituximab can rarely cause pulmonary toxicity.
• Rituximab-associated lung disease poses a mortality risk despite early detection.

Purpose of the Study:

• To highlight the occurrence and management of Rituximab-associated lung disease.
• To emphasize the importance of early diagnosis and intervention.

Main Methods:

• Review of reported cases and clinical guidelines.
• Exclusion of concurrent pathologies like infections.
• Diagnostic confirmation via radiological imaging and histology.

Main Results:

• Pulmonary toxicity typically manifests around the fourth Rituximab cycle.
• Prompt initiation of corticosteroid therapy is recommended.
• Patient counseling on respiratory symptoms is crucial.

Conclusions:

• A high index of suspicion is necessary for diagnosing Rituximab-induced lung injury.
• Integrated diagnostic and therapeutic strategies improve patient outcomes.
• Awareness and patient education are key to managing this rare complication.